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Background: 177Lu-[DOTA0, Tyr3]-octreotate (177Lu-octreotate) is used for treatment of patients with somatostatin
receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rarely seen, and
optimization of treatment protocols is needed. In vitro studies have shown that irradiation can up-regulate
the expression of SSTR1, 2 and 5, and increase 177Lu-octreotate uptake.
The aim of the present study was to examine the anti-tumor effect of a 177Lu-octreotate priming dose followed 24 h
later by a second injection of 177Lu-octreotate compared to a single administration of 177Lu-octreotate, performed on
the human small intestine neuroendocrine tumor cell line, GOT1, transplanted to nude mice.
Results: Priming resulted in a 1.9 times higher mean absorbed dose to the tumor tissue per administered activity,
together with a reduced mean absorbed dose for kidneys. Priming gave the best overall anti-tumor effects. Magnetic
resonance imaging showed no statistically significant difference in tumor response between treatment with and
without priming. Gene expression analysis demonstrated effects on cell cycle regulation. Biological processes
associated with apoptotic cell death were highly affected in the biodistribution and dosimetry study, via differential
regulation of, e.g., APOE, BAX, CDKN1A, and GADD45A.
Conclusions: Priming had the best overall anti-tumor effects and also resulted in an increased therapeutic window.
Results indicate that potential biomarkers for tumor regrowth may be found in the p53 or JNK signaling pathways.
Priming administration is an interesting optimization strategy for 177Lu-octreotate therapy of neuroendocrine
tumors, and further studies should be performed to determine the mechanisms responsible for the reported
effects.
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177Lu-[DOTA0, Tyr3]-octreotate (177Lu-octreotate) is
used to treat patients with somatostatin receptor
(SSTR)-positive neuroendocrine (NE) tumors. The cure
rate after 177Lu-octreotate is high in animal models
xenotransplanted with human NE tumors [1–5]. In
clinical studies, on the other hand, anti-tumor effects
have been moderate, with complete remission in ap-
proximately 2% and partial remission in <30% of patients
[6, 7]. Therefore, the clinical treatment protocol needs
to be optimized. Optimization could be performed by
either (1) reducing the absorbed dose to critical non-
tumor tissues, and hence reduce detrimental side effects,
in order to be able to increase the administered activity
and thereby obtain better anti-tumor effects and/or (2)
increase the therapeutic effects in tumor tissues without
increasing the administered activity. The latter could be
achieved by, e.g., up-regulation of SSTR expression in
tumor cells, thereby increasing 177Lu-octreotate uptake
in tumor tissue [8, 9].
We have previously demonstrated up-regulation of
SSTR expression on NE tumor cells after ionizing
radiation in vitro [10, 11]. Up-regulation of SSTR1, 2,
and 5 was found after irradiation, but there was no
correlation to absorbed dose (0.12–8 Gy, X-rays). To
clarify these mechanisms and obtain a better prediction
of the effects in the clinical setting, appropriate animal
models are needed. Human NE tumors xenografted to
immunosuppressed mice provide such a model for
evaluation of different treatment regimes. In a mouse
xenograft model with the human small intestine-
neuroendocrine tumor (SI-NET) GOT1 cell line xeno-
transplanted to nude mice, the uptake of a subsequent
injection of 0.5 MBq 111In-octreotate in tumor was
higher following an injection of 7.5 MBq 177Lu-octreo-
tate (a non-curative amount) than following an injection
of 30 MBq 177Lu-octreotate (a curative amount) [12, 13].
Furthermore, the optimal time between administration
of 177Lu-octreotate and higher concentration of 111In-
octreotide was 1 day or 3–13 days in GOT1 tumors on
nude mice. The increased uptake of 111In-octreotate in
tumor tissue may be due to up-regulation of SSTR
expression. Based on these results, we hypothesize that a
non-curative amount of 177Lu-octreotate as a priming
dose increases the tumor uptake of subsequently admin-
istered 177Lu-octreotate in NE tumors, leading to an in-
creased tumor-absorbed dose and anti-tumor effect.
Clinical studies frequently use fractionated therapy to
better monitor toxicity effects. However, administered
activities are often of similar size and separated by sev-
eral weeks with the aim to reduce toxic effects rather
than to increase the activity uptake in the tumor [14].
Furthermore, to our knowledge, there are no studies in-
vestigating the effects of a priming treatment scheduleon either tumor or non-tumor tissues. Up-regulation of
SSTR expression by a priming administration could
potentially reduce the problem with receptor saturation
in SSTR-expressing tumors when large amounts of
177Lu-octreotate are administered.
Before a new treatment protocol can be adopted, the
effect of priming on uptake and absorbed dose to nor-
mal tissues should be evaluated. The critical organs in
177Lu-octreotate therapy are the bone marrow (acute ef-
fects, mostly transient) and the kidneys (late effects).
The therapeutic window (or therapeutic index) gives the
relation between the amount of 177Lu-octreotate that
causes the therapeutic effect and the amount that causes
toxicity.
The aim of the present study was to examine if a
priming administration of 177Lu-octreotate 24 h before a
subsequent 177Lu-octreotate administration increases the
anti-tumor effect of 177Lu-octreotate in GOT1 tumor
tissue in mice, compared with a single administration of
the total amount of 177Lu-octreotate. Furthermore, we
also determined the effect of priming on the biodistribu-
tion of 177Lu-octreotate to evaluate the effect on the
therapeutic window.
Methods
Tumor model and animal handling
GOT1 (an SI-NET cell line) tissue was transplanted sub-
cutaneously in the neck of 4-week-old female BALB/c
nude mice (Charles River Laboratories International,
Inc., Japan and Germany) as previously described [15].
Transplantation was performed under anesthesia using
Ketaminol® vet. (Intervet AB, Sweden, 50 mg/ml) and
Domitor® vet. (Orion Pharma Animal Health, Sweden,
1 mg/ml). Antisedan (Orion Pharma Animal Health,
Sweden, 5 mg/ml) was used as an antidote after
transplantation.
During the magnetic resonance imaging (MRI) experi-
ments, the animals were anesthetized using a mixture of
air and ~2% isoflurane (Isoba vet., Schering-Plough Animal
Health, Farum, Denmark). Body temperature was main-
tained with a heating pad under the animal, and a pressure
sensitive pad was used for respiratory triggering.
All 177Lu-octreotate or NaCl injections were adminis-
tered i.v. into the tail vein. Water and autoclaved food
were available ad libitum. At the end of the study,
Pentobarbitalnatrium vet. (Apotek Produktion & Labor-
atorier AB, Sweden, 60 mg/ml) was administered i.p.
followed by cardiac puncture.
Radiopharmaceutical
177LuCl3 and [DOTA
0, Tyr3]-octreotate were purchased
from the Nuclear Research and Consultancy Group (IDB
Holland, the Netherlands). Radiolabeling of [DOTA0,
Tyr3]-octreotate with 177Lu was performed according to
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177Lu-octreotate solution was performed using instant
thin layer chromatography (ITLCTM SG, PALL Corpor-
ation, USA) with 0.1 M sodium citrate, pH 5 (VWR
International AB, Sweden), as the mobile phase. The
fraction of peptide-bound 177Lu was >98%, and the
specific activity was approximately 26 MBq/μg octreo-
tate. The 177Lu activity in each syringe was measured
prior to and after administration of the radiopharmaceu-
ticals with a well-type ionization chamber (CRC-15R,
Capintec, USA). A Wallac 1480 gamma counterFig. 1 Experimental workflow. GOT1-bearing BALB/c nude mice were divid
two therapeutic studies. In these studies, tumor-bearing mice received eith
followed by a subsequent injection of 177Lu-octreotate 24 h later. Mag
tumor volume, tumor morphology, and gene expression of tumors we
dissected; yellow indicates that radioactivity measurements and dosime
kidneys, liver, lungs, pancreas, spleen, and tumor; blue indicates that tu
and subjected to morphological and immunohistochemical analyses; gr
by RNA extraction and gene expression analysis(WIZARD™ 3”, Wallac Oy, Finland) with a ±10% energy
window over the 208-keV photon peak was used to
measure the 177Lu activity in the samples.
Overall study design
The present investigation consisted of three different
studies: one biodistribution and dosimetry study includ-
ing MRI examinations and two therapeutic studies. For
an overview of experimental groups, see Fig. 1. We ini-
tially studied if different biodistributions and absorbed
doses were obtained for tumor and normal tissues usinged into three studies: one biodistribution and dosimetry study and
er a single injection of 177Lu-octreotate or a priming administration
netic resonance imaging (MRI), biokinetics, mean absorbed dose,
re analyzed. Dagger symbol indicates that animals were killed and
tric calculations were performed on samples from adrenals, blood,
mor samples were fixed in formaldehyde, embedded in paraffin,
een indicates that tumor samples were snap frozen in lN2 followed
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study). Then we compared the therapeutic effects of
those schedules but also included other combinations of
priming and subsequent injected amounts in order to
study if other schedules gave similar effects or were
more optimal (therapeutic studies).
In total, 70 GOT1 tumor-bearing nude mice (mean
weight 21 g, SEM = 0.27 g) were included in the experi-
ments. There was a large variation in tumor volume at
the start of experiments (49–1400 mm3). Therefore, ef-
forts were made to obtain a similar distribution of tumor
size in all groups at the start of experiments (tumor vol-
ume distribution in the different groups is shown in
Fig. 1). At the end of the experiments, tumor tissue from
all animals were excised and divided into two halves:
one half was instantly frozen in liquid nitrogen for gene
expression analysis and the other half was weighed and
placed in neutral buffered formaldehyde for radioactivity
measurements and subsequent paraffin embedding.
Biodistribution and dosimetry study
The biodistribution of 177Lu-octreotate in GOT1 tumor-
bearing mice was determined as well as the effects on
the activity concentration in tumor and normal tissues
when a priming administration was given before a subse-
quent administration of 177Lu-octreotate.
Two groups (n = 9/group) of GOT1 tumor-bearing
mice (5.1 months old) were given 177Lu-octreotate. One
group received a priming administration of 5 MBq
followed by 10 MBq of 177Lu-octreotate 24 h later. The
other group received a single injection of 15 MBq 177Lu-
octreotate. To avoid complete tumor remission in the
evaluation of therapeutic effects after priming adminis-
tration, a total activity of 15 MBq (0.6-μg peptide) was
chosen. Animals were killed 24, 72, or 168 h after the
last injection (n = 3/time point). Non-treated control ani-
mals (n = 2/time point) were injected with NaCl. Blood
samples were collected by cardiac puncture. The adre-
nals, kidneys, liver, lungs, pancreas, spleen, and tumor
were excised from each animal for 177Lu activity meas-
urement using the gamma counter.
The 177Lu activity concentration in each tissue was
calculated as percent of injected activity per gram tissue
(%IA/g), and the tumor-to-normal tissue activity concen-
tration ratio (T/N) was determined [16]. For animals re-
ceiving two injections (5 + 10 MBq) of 177Lu-octreotate,
the 177Lu activity concentration was estimated for the
10 MBq administration only (in order to determine the
biokinetics for the second administration, since the
5 MBq administration was supposed to act as priming
administration and not as a therapeutic activity), based
on measured 177Lu activity concentration (MBq/g) after
5 + 10 MBq and subtraction of the contribution from the
priming administration. This contribution was estimatedby assuming that the 5 MBq priming activity had the same
biokinetics as the single administration of 15 MBq but ex-
trapolated to the time points 48, 96, and 192 h after injec-
tion, corrected for radioactive decay.
The mean absorbed dose to the tissue was calculated
according to the Medical Internal Radiation Dose Com-
mittee (MIRD) pamphlet 21 formalism [17]:
D rT ;TDð Þ ¼
~A rS; TDð Þ
X
i
EiY iϕ rT←rS; Ei;TDð Þ
M rT ;TDð Þ ;
where ~A rS; TDð Þ ¼
Z TD
0
A rs; tð Þ dt is the time-
integrated activity in the source organ rs at the time of
dose determination TD =∞. The mean energy emitted
per nuclear transformation, ∑iEiYi, was approximated for
177Lu to 147.9 keV/decay [18, 19], including β− particles,
Auger, and conversion electrons. The contribution from
photons was not accounted for, and the target organ (rT)
was set to be the same as the source organ (rs) in all cal-
culations. This means that the mean absorbed dose to
all organs might be somewhat higher (in the order of a
few percent) than the data presented here. However, the
absorbed fraction, ϕ(rT← rS, Ei,TD), was set to 1 for all
tumors and organs, which will give an overestimation in
mean absorbed dose to the tumor of only up to approxi-
mately 10% [20]. M(rT,TD) was the mass of the tissue.
The estimated absorbed doses are considered appropri-
ate, especially when considering the uncertainties in
pharmacokinetic data available.
Therapeutic studies
Study 1: GOT1 tumor-bearing mice (11.5 months old)
were injected with a priming administration of 5 or
10 MBq of 177Lu-octreotate followed by a second admin-
istration (24 h later) of 10 or 5 MBq 177Lu-octreotate,
respectively. Thus, each mouse received a total activity
of 15 MBq (0.6 μg peptide, n = 5/group), which was
chosen to avoid complete tumor remission. A third
group received 30 MBq (1.2 μg peptide) as a single injec-
tion (n = 5/group).
Study 2: GOT1 tumor-bearing mice (6.0 months old)
were injected with a single administration of 15 MBq of
177Lu-octreotate, or different priming activities of 0.5,
2.5, 5, or 10 MBq of 177Lu-octreotate, followed by a sec-
ond administration (24 h later) of 14.5, 12.5, 10, or
5 MBq 177Lu-octreotate, respectively, resulting in a total
administrated activity of 15 MBq (0.6-μg peptide) to all
groups (n = 5/group). Non-treated control animals (n = 6)
were included in the study.
During the study period, tumor size and animal weight
measurements were performed twice a week. Tumor size
was determined using digital slide calipers by measuring
the longest diameter a and the two perpendicular
Dalmo et al. EJNMMI Research  (2017) 7:6 Page 5 of 16diameters b and c. Assuming the form of an ellipsoid,




The animals were killed 41 days after the last injection
of 177Lu-octreotate. Tumor tissue was harvested and an-
alyzed as described under the “Overall study design”
section.
MRI examinations
Animals from the biodistribution and dosimetry study
(5 + 10 MBq: n = 6 and 15 MBq: n = 6) were each ex-
amined three times using MRI (Fig. 1): at day -6, day -1
(5 + 10 MBq group), day 0 (15 MBq group), day 3 (n = 3
mice/group), and day 7 (n = 3 mice/group). Tumor vol-
ume was determined using a caliper prior to all MRI ex-
aminations, and the animals were killed after the third
examination. All tumors were resected and weighed for
volume determination (assuming a density of 1 g/cm3).
MRI experiments were performed using a dedicated
small animal 7 T MRI system (Bruker BioSpin MRI
GmbH, Germany; software: ParaVision 5.0) equipped
with a 72-mm transmit volume coil and a 4-channel
array rat brain receiver coil (RAPID Biomedical GmbH,
Germany). A T2-weighted, 2D RARE (rapid acquisition
with relaxation enhancement) sequence was used with
respiration triggering and fat suppression (repetition
time, 4200 ms; effective echo time, 30 ms; signal
averages, 3; turbo factor, 4) [21]. Image field-of-view
covered the tumor, using ~160 * 160 μm2 pixel size and
700-μm slice thickness (contiguous slices).
Images were processed on a PC workstation using an
in-house-developed MATLAB software (R2011b, TheFig. 2 MRI of a GOT1 xenograft. a MRI of a representative GOT1 tumor (anim
administration) after delineation for volume calculation. The fluctuating intra-t
both viable (hyper-intense) and necrotic (hypo-intense) regions. The coil sens
than more distant tissues, which confounds histogram analysis. This is correct
profile) and 3 × 3 median noise filtering has been appliedMathWorks, USA). All images were subjected to histo-
gram equalization for homogeneity correction (due to the
surface coil sensitivity profile) and a 3 * 3 median filter to
reduce random noise (Fig. 2a, b). Each tumor was manu-
ally delineated on all slices, and volume was calculated by
multiplying the total number of voxels with the voxel vol-
ume [22]. Tumor volumes determined by MRI and cali-
pers at the day of sacrifice were compared with the
volumes of the resected tumors. Histograms were created
of the voxel intensity distribution within each tumor, and
the histogram skewness was used as a surrogate marker of
tumor viability, where a positive skewness would indicate
an abundance of low-intensity voxels, typical of necrotic
regions, and a negative skewness would indicate a greater
amount of viable tumor tissue, typically seen as high-
intensity regions in T2-weighted images.
Transcriptional analysis
Frozen tumor tissue was homogenized using the Tissue-
Lyser LT (Qiagen, Germany), and total RNA was extracted
using the RNeasy Lipid Tissue Mini Kit (Qiagen) accord-
ing to the manufacturer’s instructions. RNA quantity was
determined using an ND-1000 Spectrophotometer (Nano-
Drop Technologies, DE, USA), and RNA quality was de-
termined with the RNA 6000 Nano LabChip Kit and
Agilent 2100 Bioanalyzer (Agilent Technologies, CA,
USA). RNA samples with RNA integrity numbers above
6.0 were used for gene expression analysis.
Gene expression analysis was performed on tumor
tissues from three animals per time point from the 5 +
10 MBq and 15 MBq groups at 24 h, 72 h, 168 h, and
41 days, as well as control animals, injected with NaCl
solution for each time point (n = 2 at 24, 72, and 168 h;
n = 3 at 41 days, Fig. 1). Hybridization of the RNA
samples was performed at the Swegene Center foral no. 3 in the 5 + 10 MBq group imaged on day -1, prior to priming
umor intensity illustrates the heterogeneity of tumor tissue, containing
itivity profile makes tissues closer to the coil (bottom of image) brighter
ed for in b where histogram equalization (correcting for coil sensitivity
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on Illumina HumanHT-12 v4 Whole-Genome Expression
BeadChips (Illumina, CA, USA), containing 47,231 probes
per array. The BeadChips were analyzed using the Illu-
mina iScan N240 microarray scanner (Illumina, CA,
USA). Data pre-processing and quantile normalization
were performed on the raw signal intensities using the
BioArray Software Environment (BASE) system. Further
processing was then performed using Nexus Expression
3.0 (BioDiscovery, CA, USA) as previously described
[23, 24]. The Gene Ontology (GO) database (http://
www.geneontology.org) was used for the analysis of
associated biological processes [23]. Emphasis in this
study was placed on the analysis of differential regula-
tion associated with cell death and cell cycle regula-
tion, as these factors have previously been described
as major actors in tumor radiation response in the
clinical setting [25, 26]. The gene expression data in
this study have been deposited in NCBI’s Gene Ex-
pression Omnibus (GEO accession GSE80022).
The expression levels of SSTR1–5 in the biodistri-
bution and dosimetry study were analyzed using
quantitative reverse transcription-polymerase chain re-
action (qRT-PCR) with predesigned TaqMan® assays
(Applied Biosystems, CA, USA) specific for SSTR1–5
(Hs00265617_s1 (SSTR1), Hs00990356_m1 (SSTR2),
Hs01066399_m1 (SSTR3), Hs01566620_s1 (SSTR4),
Hs00990407_s1 (SSTR5)), GAPDH (Hs99999905_ml),
and TUBB (Hs00742828_s1). The PCR reactions were
performed in triplicate using a 7500 Fast Real-Time
PCR System (Applied Biosystems). The levels of mRNA
expression are reported relative to the two housekeeping
genes GAPDH and TUBB (2−(Ct(target gene) −Ct((GAPDH +
TUBB)/2))). All qRT-PCR reactions were performed on com-
plementary DNA (cDNA), synthesized from the same
RNA extracted for use in the microarray experiments,
using SuperScript™ III First-Strand Synthesis SuperMix
(Invitrogen, CA, USA). cDNA reactions without addition
of reverse transcriptase prior to qRT-PCR did not monitor
any interfering genomic DNA.
Morphology and immunohistochemistry
At the end of the experiments, all xenografts were har-
vested and processed for microscopic examination. The
morphology of formalin-fixed and paraffin-embedded
xenografts was examined after hematoxylin-eosin and
Masson’s trichrome staining. For immunohistochemical
analysis, sections were placed on positively charged glass
slides and treated with EnVision™ FLEX Target Retrieval
Solution (high pH) using a PT-Link (Dako, Denmark).
Immunohistochemical staining was performed in an
Autostainer Link using EnVision™ FLEX according to
the manufacturer’s instructions (Dako). Positive and
negative controls were included in each run. Primaryantibodies to chromogranin A (MAB319; Merck Milli-
pore, Germany), synaptophysin (Sy38, Dako), Ki67
(AB9260; Merck Millipore), and BAX (B-9; sc-7480;
Santa Cruz Biotechnology, CA) were used.
The effects of 177Lu-octreotate on xenografted tumors
were evaluated morphologically and graded according to
Becket et al. [27]. The percentage of Ki67-positive tumor
cell nuclei was calculated by manual counting of printed
images from “hot spots,” including >500 tumor cell nuclei.
The intensity of BAX staining was evaluated by two inde-
pendent observers and graded as absent, weak, moderate,
or strong.
Statistical analyses
All tumor volume measurements and results from the
biodistribution data for each group were expressed as
mean value and standard error of the mean (SEM) or
standard deviation (SD). Student’s t test was used to
analyze data throughout all studies between groups and
within groups at different time points using a two-tailed
unpaired t test, and p < 0.05 was considered statistically
significant.
The difference between groups regarding skewness
analyses of the MRI data after treatment was assessed
using an F test, where the skewness vs. time regression
coefficients was compared. In this test, the interaction of
time and treatment was considered.
The differential expression of transcripts (treated vs.
untreated) was determined from unfiltered microarray
probes using the Benjamini-Hochberg method with ad-
justed p < 0.01 [28]. Transcripts with ≥1.5-fold change
were considered significantly regulated compared to
controls. Enrichment analysis on gene sets to identify
over-represented GO terms for biological processes was
performed using Fisher’s exact test with p < 0.05 consid-
ered statistically significant.
Results
Biodistribution and dosimetry of 177Lu-octreotate is
significantly affected by priming administration
Mean 177Lu activity concentration in GOT1-bearing
mice at 24, 72, and 168 h after the last injection is pre-
sented in Table 1 (A). Compared with the values at 24 h,
the mean activity concentration in the tumor increased
72 h after priming but decreased for the single adminis-
tration (15 MBq), with a statistically significant differ-
ence between the treatment schedules at 72 h. In the
kidneys, the activity concentration decreased equally in
both groups, as was observed for the blood. One tumor
from the 15 MBq group (killed 72 h after injection)
showed only background levels of 177Lu activity concen-
tration. This tumor did not show the typical hyper-
intensity in the MRI examinations which was observed
for all other tumors in the study. The RNA extraction
Table 1 Biodistribution of 177Lu-octreotate in GOT1-bearing nude mice
A 177Lu activity concentration (%IA/g)
With priming, (5+) 10 MBq (n = 9) Without priming, 15 MBq (n = 8)
Tissue 24 h 72 h 168 h 24 h 72 h 168 h
Adrenals 1.4 (0.1)a 0.42 (0.20)a 0.36 (0.06) 0.60 (0.03)a 1.4 (0.1)a 0.30 (0.06)
Blood 0.013 (0.001) 0.0048 (0.0005) 0.0017 (0.0004) 0.011 (0.001) 0.0055 (0.0002) 0.0021 (0.0002)
Kidneys 4.5 (0.8) 1.5 (0.1) 0.71 (0.14)a 6.8 (0.3) 2.3 (0.4) 0.50 (0.04)a
Liver 0.094 (0.008) 0.077 (0.009) 0.070 (0.009) 0.12 (0.06) 0.10 (0.01) 0.049 (0.004)
Lungs 0.84 (0.10)a 0.43 (0.03) 0.31 (0.02)a 0.48 (0.04)a 0.33 (0.02) 0.15 (0.003)a
Pancreas 0.54 (0.02)a 0.30 (0.02) 0.18 (0.02)a 0.36 (0.03)a 0.26 (0.04) 0.062 (0.011)a
Spleen 0.080 (0.010) 0.090 (0.006) 0.090 (0.010) 0.10 (0.01) 0.088 (0.009) 0.061 (0.005)
Tumor 2.5 (0.9) 4.6 (0.8)a 1.8 (0.5) 1.6 (0.1) 1.6 (0.2)a,b 0.84 (0.31)
B Tumor-to-normal tissue activity concentration ratio (T/N)
With priming, (5+) 10 MBq (n = 9) Without priming, 15 MBq (n = 8)
Tissue 24 h 72 h 168 h 24 h 72 h 168 h
Adrenals 1.7 (0.5) 23 (9) 4.6 (1.2) 2.7 (0.4) 1.1 (0.1) 3.8 (1.6)
Blood 190 (62) 1100 (280) 1100 (360) 160 (34) 290 (21) 420 (160)
Kidneys 0.62 (0.29) 3.1 (0.7)a 2.6 (0.8) 0.23 (0.02) 0.76 (0.19)a 1.5 (0.6)
Liver 27 (10) 63 (14) 24 (5) 14 (1) 17 (2) 16 (6)
Lungs 2.9 (1.1) 10 (2) 5.4 (1.3) 3.4 (0.4) 4.9 (0.6) 5.8 (2.2)
Pancreas 4.5 (1.5) 15 (2)a 10 (3) 4.4 (0.3) 6.6 (1.1)a 12 (4)
Spleen 32 (13) 53 (11) 18 (4) 17 (1) 19 (3) 13 (5)
C Tumor cell proliferation assed by Ki67 staining (%)
With priming, (5+) 10 MBq (n = 9) Without priming, 15 MBq (n = 8) Controls
Antibody 24 h 72 h 168 h 24 h 72 h 168 h 24 h 72 h 168 h
Ki67 27 (4) 22 (2)c 25 (2)c 31 (1)c 29 (3)b 28 (2)c 45 (1)b 42 (1)b 42 (2)b
A: 177Lu activity concentration (%IA/g), B: tumor-to-normal tissue activity concentration ratio, and C: percent of tumor cells with positive immunohistochemical
staining from tumors after 5 + 10 or 15 MBq 177Lu-octreotate with or without priming activity, respectively, corrected for physical decay, in different tissues in
GOT1 tumor-bearing nude mice at 24, 72, and 168 h after injection (n = 3/group). Values for the 5 + 10 MBq group (activity concentration and T/N) were estimated
based on data from the 10 MBq administrations only i.e. therapeutic effect. Values are given as mean (SEM). Statistically significant difference (p < 0.05) between
priming and single administration and between treated animals and controls is indicated by a and c, respectively, bn = 2
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for analysis from this tumor sample, and histological
examination showed no viable tumor cells. The tumor
was therefore excluded from all analyses, but non-
tumoral tissues from this animal were still included in
the activity concentration and dosimetry calculations.
For all normal tissues except the spleen (with priming)
and adrenals (without priming), the activity concentration
decreased with time. The activity concentration after
administration without priming had an initial higher
uptake in the kidneys, liver, and spleen, but the activity
concentration decreased faster than in the priming group
to the last time point measured. In the pancreas and
lungs, the activity concentration decreased with time for
both groups but was higher when using priming.
The mean T/N ratios are presented in Table 1 (B). The
T/N ratios for the blood, kidneys, liver, and spleen werehigher when a priming administration was given. The
pancreas, adrenals, and lungs in the priming group had
a peak in T/N ratio after 72 h and decreased thereafter,
while the T/N ratio increased with time in the group
without priming. There was a statistically significant dif-
ference in T/N ratios in the kidneys and pancreas at
72 h between animals receiving treatment with and
without priming.
The estimated mean absorbed doses with or without
priming are given in Table 2. The mean absorbed dose
to the tumor per administered activity was 0.51 Gy/MBq
after priming and 0.27 Gy/MBq without priming admin-
istrations. The kidneys received a lower mean absorbed
dose per administered activity with priming compared to
no priming (0.25 vs. 0.32 Gy/MBq). Priming resulted in
higher mean absorbed dose per administered activity for
the adrenals, lungs, pancreas, and spleen.
Table 2 Mean absorbed dose calculations of 177Lu-octreotate in
GOT1-bearing nude mice
Tissue Mean absorbed dose per administered activity (Gy/MBq)









The mean absorbed dose per administered activity after 10 or 15 MBq
177Lu-octreotate (Gy/MBq) (with and without priming, n = 9/group),
respectively. Values for the 5 + 10 MBq group were estimated from the
values for the 10 MBq administrations only
an = 8
Fig. 3 Anti-tumor effect of 177Lu-octreotate on GOT1-bearing nude mice. T
studies 1 and 2. a Evaluation of the anti-tumor effect of the priming treatmen
b Results from groups receiving a smaller priming administration and larger s
(0.5 + 14.5 and 2.5 + 12.5 MBq, respectively). c Anti-tumor effect in groups
administration than in the biodistribution and dosimetry study (10 + 5 MBq) o
animals and animals treated with 15 MBq 177Lu-octreotate are also shown in
and 2 (note the scale of the y axis). The relative tumor volume reduction was
(study 1 but not study 2) compared with the 15 MBq group (Student’s t test,
respectively. Symbols represent mean relative tumor volumes. Error bars indica
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priming administration
The results from the therapeutic studies 1 and 2 are
shown together, demonstrating the relative tumor vol-
ume vs. time after administration in animals receiving
the treatment schedules used in the biodistribution and
dosimetry study (5 + 10 and 15 MBq, Fig. 3a), a smaller
priming administration and larger subsequent adminis-
tration (0.5 + 12.5 and 2.5 + 12.5 MBq, Fig. 3b), and a lar-
ger priming administration and smaller subsequent
administration or a larger single administration (10 + 5
and 30 MBq, Fig. 3c). The smallest relative tumor volumes
were reached after 9–16 days in the groups receiving a
priming administration, with the best therapeutic effects
in the 2.5 + 12.5 MBq and 5 + 10 MBq groups. A statisti-
cally significant difference in minimum relative tumor vol-
ume was observed between these treatment groups and
the 15 MBq group (p < 0.05). In the groups receiving a
priming activity, the minimum relative tumor volumes
were largest in the 0.5 + 14.5 MBq and 10 + 5 MBq groupshe relative tumor volume vs. time after last administration is shown for
t schedule used in the biodistribution and dosimetry study (5 + 10 MBq).
ubsequent administration than in the biodistribution and dosimetry study
receiving a larger priming administration and smaller subsequent
r a larger single administration (30 MBq). Measurements for non-treated
a–c for comparison. d Mean animal body weight in therapeutic studies 1
statistically significant in the 2.5 + 12.5 MBq group and 5 + 10 MBq group
p < 0.05), shown as the plus symbol at the top of the graph in a and b,
te SEM. Black arrow indicates start of treatment
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administration was given (15 and 30 MBq). No statistically
significant adverse effects on animal weight were seen in
either study 1 or study 2 (Fig. 3d, note the scale of the y
axis). All measurement data on relative tumor volumes
with statistical test results between all groups are available
in Additional file 1: Table S1.
The tumor regrowth period, i.e., the time for the
tumor to grow back to the tumor volume at the start of
the treatment, was 21–28 days for the groups treated
with 0.5 + 14.5, 2.5 + 12.5, 10 + 5 (studies 1 and 2), 15,
and 30 MBq 177Lu-octreotete. However, the tumor re-
growth time was longer, i.e., 35–41 days, for tumors
treated with 5 + 10 MBq (studies 1 and 2).
MRI examinations suggest heterogeneity of GOT1
xenografts
Tumors in all animals but one (15 MBq group, killed 72 h
after injection, excluded from the study as described
above) were well visualized in the MR images (Fig. 2).
On average, tumor volumes determined by calipers
were 20% smaller than those of the resected tumors.
Corresponding MRI volumes were 1% larger than the
resected tumors. The mean tumor volume regression
rate after treatment was slightly higher in the priming
group: −5.7 vs. −5.1%/day, but the difference was not
statistically significant (p = 0.68) (Fig. 4a) nor were there
statistically significant differences in the group mean
tumor volumes after treatment (day 3: p = 0.22, day 7:
p = 0.59, and day 3 + 7: p = 0.38).
The voxel intensity analysis revealed a trend common
for both groups, where skewness increased beforeFig. 4 MRI of GOT1 xenograft in the biodistribution and dosimetry study. a
after treatment. The mean tumor volume in the 5 + 10 MBq group decreas
5.1%/day in the 15 MBq group. b The mean skewness of the tumor voxel h
was a shift towards more positive skewness before treatment, with a revers
pronounced in the 15 MBq group (red line). The gray arrow indicates the in
10 MBq. Error bars indicate SDtreatment, but decreased monotonically after treatment
(Fig. 4b). The skewness in the 15 MBq group seemed to
decrease at a higher rate than the 5 + 10 MBq group, but
the difference was not statistically significant (p = 0.31).
Enhanced pro-apoptotic and anti-proliferative
transcriptional response in GOT1 tumors after
priming administration
In total, 91, 380, 544, and 531 transcripts were signifi-
cantly regulated in animals treated with 5 + 10 MBq
177Lu-octreotate at 24 h, 72 h, 168 h, and 71 days, respect-
ively; 159, 214, 378, and 405 were the corresponding num-
bers in animals treated with 15 MBq 177Lu-octreotate. No
significant regulation of SSTR1–5 or the neuroendocrine
markers chromogranin A (CHGA) and synaptophysin
(SYP) was found in the global transcriptional analysis.
Figures 5 and 6 show the differentially regulated genes
(treated vs. untreated) associated with apoptotic cell death
and cell cycle regulation in tumor samples from animals
injected with 5 + 10 or 15 MBq 177Lu-octreotate 24 h,
72 h, 168 h, and 41 days after the last injection. The genes
associated with apoptotic cell death were divided into
pro-apoptotic, anti-apoptotic, and general apoptosis-
related genes (Fig. 5a–c), according to GO-term associ-
ation. A larger number of up-regulated pro-apoptotic
genes were found in the 5 + 10 MBq group (BAX,
GADD45A, and ZAK) compared to the 15 MBq group
(BAX). One down-regulated gene (CRYAB) was found
among the anti-apoptotic genes in the 5 + 10 MBq
group, while two anti-apoptotic genes (HSPB1 and
ADORA2A) were significantly up-regulated in the
15 MBq group at 41 days after the last injection. NoRelative mean tumor volume for 5 + 10 and 15 MBq groups vs. time
ed by 5.7%/day after treatment, whereas the corresponding value was
istograms is shown vs. time after administration. The general trend
ed direction after treatment, where the negative shift is more
jection of 5 and 15 MBq and the black arrow indicates injection of
Fig. 5 Expression of genes associated with cell death. Differential expression of genes associated with apoptotic cell death (a pro-apoptotic
genes, b anti-apoptotic genes, c general apoptosis-related genes) in tumor samples from animals treated with 15 or 5 + 10 MBq 177Lu-octreotate,
compared with untreated controls after 24 h, 72 h, and 41 days after the last injection. No genes related to non-apoptotic cell death were found
in the analysis, and no genes associated with apoptotic cell death were found at 168 h after injection. Transcripts with changed expression ≥1.5-fold
and an adjusted p < 0.01 were considered significantly regulated; association to biological process was performed using the GO database
with a p value cutoff of <0.05
Fig. 6 Expression of genes associated with cell cycle regulation. Differential expression of genes associated with cell cycle regulation
(a pro-proliferative genes, b anti-proliferative genes, c general cell cycle regulation-related genes) in tumor samples from animals treated
with 15 or 5 + 10 MBq 177Lu-octreotate, compared with untreated controls after 24 h, 72 h, 168 h, and 41 days after the last injection.
Transcripts with changed expression ≥1.5-fold and an adjusted p < 0.01 were considered significantly regulated; association to biological
process was performed using the GO database with a p value cutoff of <0.05
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death at 168 h after injection, and genes associated with
non-apoptotic cell death were not differentially regu-
lated in any treatment group at any time point. In order
to validate alterations in apoptosis-related genes after
177Lu-octreotate, we analyzed the expression of BAX
protein in xenografted tumors by immunohistochemis-
try. The BAX protein was found to be strongly
expressed in all tumors, with no difference in staining
intensities between experimental groups.
Genes associated with cell cycle regulation were
divided into pro-proliferative, anti-proliferative, and
general cell cycle regulation-related genes (Fig. 6a–c).
Three pro-proliferative genes were regulated in the 5 +
10 MBq group at 72 h after administration, one up-
(CCND3) and two down-regulated (DLGAP5 and
CDCA5). A larger amount of anti-proliferative genes
were regulated in the 5 + 10 MBq group (CDKN1A,
BTG3, GADD45A, KAT2B, CDK6, RHOB, ZAK, FOXO4,Fig. 7 Expression of SSTR1–5 in GOT1 tumors after 177Lu-octreotate exposu
by qRT-PCR in GOT1 tumors. Tumors were analyzed 1, 3, and 7 days a
as a single dose. Each symbol represents one tumor. C untreated contrand AIF1) compared to the 15 MBq group (CDKN1A
and CDK6), and most genes were up-regulated. In order
to validate the anti-proliferative effects after 177Lu-
octreotate, we analyzed the percentage of Ki67-positive
tumor cells in xenografted tumors by immunohisto-
chemistry. We confirmed a reduction of Ki67-positive
tumor cells in xenografts from treated animals compared
to untreated controls (Table 1 (C)).
The gene expression of SSTR1–5 was analyzed by
qRT-PCR. Priming administration of 5 MBq followed by
10 MBq of 177Lu-octreotate 24 h later did not change
the SSTR1–4 gene expression in the tumors when com-
pared with tumors that had received a single dose of
15 MBq 177Lu-octreotate or untreated tumors (Fig. 7).
One day after treatment, SSTR5 was found down-
regulated in tumors treated with a single administration
compared with priming administration. However, the
SSTR5 expression in tumors exposed to a single dose was
not changed when compared with untreated tumors.re. Gene expression of SSTR1–5 relative to GAPDH and TUBB analyzed
fter treatment with 5 + 10 MBq priming or 15 MBq 177Lu-octreotate
ol tumors. Line represents mean of triplicates. *p < 0.05
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Microscopic examination of xenografts in the biodistri-
bution and dosimetry studies confirmed NE tumors with
a morphology typical of GOT1. The percentage of tumor
cells was in the 70–90% range. Examination of xeno-
grafts from the therapeutic studies showed heterogeneity
of tumors, with viable NE tumor cells alternating with
areas of fibrosis and inflammation, characteristic for
tumor regression. Immunohistochemical staining for the
NE markers chromogranin A and synaptophysin showed
strong staining of the tumor cells (cf Fig. 8).
Histologic grading of tumor regression in the thera-
peutic study showed marked tumor regression (grades
1a and 1b) only in tumors treated with priming.Fig. 8 Morphology of GOT1 xenograft after 177Lu-octreotate
exposure. This tumor was harvested from a mouse treated with a
priming administration (2.5 MBq) followed by a subsequent dose
(12.5 MBq) of 177Lu-octreotate 24 h later. Maximal reduction of
tumor volume (67%) was noted 9 days after treatment. Thereafter,
the tumor started to grow and was harvested on day 41 after the
last injection. a The xenograft contained areas of fibrosis as well as
areas of viable tumor cells (left). Viable tumor cells from the boxed
area are shown at high magnification (right). Hematoxylin and eosin
stain. b Tumor regression in xenografts is highlighted by staining for
collagen (blue, Masson’s trichrome stain). c The NE differentiation of
the xenograft was confirmed by positive staining for chromogranin
A (brown). Viable tumor cells had a granular cytoplasmic staining as
shown at high magnification (right panel). Scale bars equal 1 mm
(left panel) and 50 μm (right panel)Discussion
In the present study, we evaluated the possibility to in-
crease the tumor-specific uptake of 177Lu-octreotate in
GOT1 tumor-bearing BALB/c nude mice. A priming ad-
ministration of 177Lu-octreotate was given 24 h before a
subsequent administration to evaluate whether a better
anti-tumor effect was obtained compared with that ob-
tained after a single administration. We show that the
mean absorbed dose to the tumor was higher after prim-
ing, and the anti-tumor effects were more pronounced
in some of these groups as compared with a single
administration. Differences in response after priming
were also illustrated by gene expression analysis. Due to
a lower mean absorbed dose to the kidneys, priming also
resulted in an increased therapeutic window.
The activity concentration in the tumor was higher
using a priming administration and increased until 72 h
after the last injection. This increase could be explained
by higher SSTR expression, since uptake can continue as
long as 177Lu-octreotate is present in the blood. In
several in vivo studies with 177Lu-octreotate treatment of
NE tumors, rapid tumor shrinkage has been associated
with a long retention time or even increasing tumor
activity concentration over time [1, 13, 29]. This type of
uptake and retention of 177Lu-octreotate was also found
in the present study, with a significantly higher uptake
after 72 h in the priming group (5 + 10 MBq) compared
with the 15 MBq group. However, 177Lu-octreotate was
probably degraded and released faster from the cells
after 5 + 10 MBq than after 15 MBq administrations.
The decrease in activity concentration in the tumor was
nearly 60% between 72 and 168 h in the 5 + 10 MBq group
compared with a 25% decrease for the 15 MBq group.
Despite these results, the activity concentration (in %IA/g)
was still higher in the 5 + 10 MBq group at 168 h.
In non-tumoral tissue, the mean activity concentration
after 24 h was higher in the SSTR-expressing tissues
after priming (5 + 10 MBq group), which indicates that
SSTR could also be up-regulated in these tissues. These
findings are not in accordance with previous results,
which did not show any increased 177Lu-octreotate up-
take in normal tissues [12]. An additional explanation to
the higher activity concentrations found in tumoral and
non-tumoral SSTR-expressing tissues might be that the
priming administration influences vascular perfusion.
Previous studies have shown an increase in perfused
blood vessels in tumor tissue shortly after irradiation
with X-rays (studied with Hoechst 33342 and DCE-
MRI). This was followed by a decrease in perfusion at
later times after irradiation, and a subsequent increase
to control levels at 7 to 11 days after irradiation [30, 31].
This indicates that priming might increase perfusion in
the tissue, resulting in an increased tumor uptake of the
second injection of 177Lu-octreotate. Since the activity
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tumor tissue than in the kidneys and in the blood, the
T/N ratios for the kidneys and blood were higher after
priming, which is reflected by differences in mean
absorbed dose. These findings indicate that the risk of
renal and bone marrow toxicity would be lower or simi-
lar if priming was used, which would expand the thera-
peutic window; the activity concentration measured in
the blood has been shown to closely mimic the activity
concentration in the bone marrow [32]. Nevertheless,
the mechanisms for increased 177Lu-octreotate uptake in
tumor and non-tumor SSTR-expressing tissues still need
to be identified.
To study the anti-tumor effect of priming, the treatment
schedules used in the biodistribution and dosimetry study
(5 + 10 and 15 MBq) were studied again in the therapeutic
studies. However, since the 15 MBq treatment resulted in
a lower mean absorbed dose to the tumors, a higher single
administration activity (30 MBq) was also studied. Several
other treatment schedules involving differently sized prim-
ing and subsequent administrations (all equaling a total of
15 MBq) were also studied in the therapeutic setting, in
order to establish the optimal ratio between priming and
subsequent administration amounts. The relative volumes
from each group at each measurement time were tested
using the Lilliefors test. The null hypothesis that the data
come from a normally distributed population could not be
rejected in any group at any time point (p value threshold
<0.05). We therefore decided that the t test was valid for
these comparisons. The best overall therapeutic effect was
found for the 5 + 10 MBq groups. Lower and higher prim-
ing activities were not as effective even though a statisti-
cally significant difference was seen between the 15 MBq
and 2.5 + 12.5 MBq groups when the minimum tumor
volume was reached (days 16–23). To further optimize
177Lu-octreotate therapy, and increase the cure rate, the
long-term anti-tumor effects of priming must be ex-
amined in more detail. Not surprisingly, the compari-
son between the relative tumor volumes in treated
and non-treated animals showed that both types of
treatment schedules (with or without a priming ad-
ministration) are better than no treatment at all.
However, statistically significant differences in mean
relative tumor volume between treated and untreated
animals were generally prolonged in time in animals
receiving a priming treatment schedule, compared
with the single administration groups. No statistically
significant body weight loss was observed in either of
the therapeutic studies. However, further studies on
the difference in long-term adverse effects between
different treatment schedules are needed, especially
concerning adverse effects on, e.g., the kidneys.
The growth rate of GOT1 tumors differs much be-
tween animals within a transplantation batch, whichresults in a large variation in tumor sizes at a certain
time point. Therefore, efforts were made to obtain a
similar distribution of tumor sizes between the groups,
since an inverse linear relationship between tumor size
and 177Lu-octreotate concentration has been seen in an-
other tumor type, the NCI-H69 small cell lung cancer
[33], although no such data are found for GOT1. Fur-
thermore, the tumor take is relatively low for GOT1,
which also has a long tumor doubling time. Therefore,
despite large efforts, variations in tumor size distribution
between groups were inevitable, although no statistically
significant difference in tumor volume was seen between
any of the treatment groups before treatment start. This
variation can be one reason why, e.g., the tumor regres-
sion in studies 1 and 2 for the 5 + 10 MBq group deviated.
In the present study, a total activity of 15 MBq (0.6-μg
peptide) was chosen (a) to avoid complete tumor remis-
sion and (b) to be able to assess whether priming adminis-
tration improves the therapeutic effect of 177Lu-octreotate.
In a previous study on nude mice transplanted with
GOT1 tumors, some of the mice that received 30 MBq
177Lu-octreotate (with a peptide amount of 1 μg) obtained
complete tumor remission [1]. The moderate peptide
amount was also chosen to avoid possible receptor satur-
ation [13, 33]. Saturation was also avoided by giving the
second administration no earlier than 24 h after the prim-
ing activity. During this time period, the 177Lu-octreotate
in the priming administration would have had time to
internalize and the receptors to recycle to the cell mem-
brane [13, 34, 35]. In AR42J tumors transplanted in Lewis
rats, internalization was fast (within 10 min) and recycling
was completed within 24 h after administration of the
somatostatin analog ([Tyr3, Thr8]-octreotide, TATE) [36].
Irradiation-induced SSTR up-regulation was not con-
firmed with either microarray or qRT-PCR analysis
after either priming or single administration. This was
unexpected, since we have previously demonstrated
radiation-induced up-regulation in vitro (by qRT-PCR),
and an in vivo study demonstrated increased concen-
tration of radiolabeled octreotide after priming but
without a direct proof of SSTR up-regulation [10–13].
However, one probable reason why no up-regulation of
SSTR was found in the present study is that the ana-
lyses were made at too late time points (24 h, 72 h,
168 h, and 41 day after the last injection). Down-
regulation of SSTR2 after a single injection of octreo-
tide in AR42J-bearing CB-17 SCID mice was shown
already after 0.5 h and with a complete cell surface re-
covery of SSTR2 after 16–24 h [37]. In the same study,
differences between a continuous release with mini-
osmotic pumps of octreotide (daily) and discontinuous
administrations of octreotide (given twice daily) were
found, with increasing and decreasing tumor octreotide
uptake, respectively. The kinetics of SSTR expression
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needed to clarify the mechanisms by which priming im-
proves the uptake of 177Lu-octreotate in tumor tissue,
as well as the dose-response relation between adminis-
tered activity and SSTR expression. We have previously
reported an increased tumor uptake of 111In-octreotide
following 7.5 MBq 177Lu-octreotate in GOT1 xeno-
grafts, but not following 30 MBq 177Lu-octreotate [12, 13].
Thus, the 15 MBq single administration may be too
high to result in detectable SSTR up-regulation. Further-
more, the 5 + 10 MBq group presents a convoluted
view of the gene expression response to both the
5 MBq priming administration and to the subsequent
10 MBq administration.
Caliper measurements of tumor volume are prone to
measurement errors stemming from, e.g., skin thick-
ness, operator bias, and differences in tumor shape and
location. These errors may conceal small volume
changes associated with early or small treatment ef-
fects. MRI-based tumor volume determination has been
shown to better reflect the true tumor volume, espe-
cially for small tumors, which should effectively in-
crease the sensitivity of treatment assessments [22], a
result confirmed by the present study. Nevertheless, the
MRI method could not separate the effects in the 5 +
10 MBq group from the 15 MBq group in the biodistri-
bution and dosimetry study, although confounding fac-
tors, such as differences in pre-treatment growth
kinetics and tumor size, were minimal.
MRI allows non-invasive monitoring of local intra-
tumor treatment response due to the effects on tissue
relaxation times (T1 and T2) and hence image contrast.
Increased T1 and decreased T2 values have been found
in tumors responding to chemotherapy [38, 39] which
would result in a more positively skewed voxel intensity
distribution for T2W images. However, changes in
tumor size would also affect the voxel intensity distribu-
tion if the relative volume reduction of hypo- and hyper-
intense tissue regions was not equal. In this study, tumor
volume decreased similarly in both treatment groups,
but skewness plateaued in the priming group, which
indicates a greater relative reduction of hyper-intense
(viable) tumor tissue. Neither volume nor skewness
could separate the groups on a statistically significant
level, but the reduced volume with maintained skew-
ness supported our assumption of increased treatment
effect size after priming.
To the best of our knowledge, there are no reports on
the transcriptional responses in tumor tissue after 177Lu-
octreotate therapy in vivo. In the present study, tumor
samples from animals receiving 5 + 10 or 15 MBq were
analyzed with respect to global transcriptional response.
These groups were selected to compare the transcrip-
tional effects in tumors from the priming group with thesmallest minimum relative tumor volume (5 + 10 MBq
study 1; mean relative volume 0.21 at 23 days) with
those in tumors from the single administration group
with the largest minimum relative tumor volume
(15 MBq study 2; mean relative volume of 0.78 at 9 days).
When setting the statistical thresholds for the transcrip-
tional analysis, the biological interpretation needs to be
considered in relation to the sensitivity of the analysis.
The fold-change threshold of 1.5 was chosen as a com-
promise between a complete view of the transcriptional
response and omitting responses that are not strong
enough to be reproduced or may be the result of statis-
tical noise. Our experience is that a fold change of 1.5
can be used with an acceptable sensitivity (especially in
combination with the FDR-adjusted p value threshold of
<0.01) and may also yield an understanding of potential
downstream effects which are biologically relevant com-
pared with the normal baseline gene expression [40, 41].
Results from the global transcriptional studies indi-
cated that apoptotic cell death and cell cycle regulation
are affected during the first days after 177Lu-octreotate
treatment. At 72 h after injection, BAX was up-
regulated in both treatment groups and GADD45A was
up-regulated in the tumors from animals receiving a
priming administration. Both BAX and GADD45A are
regulated by p53, and are induced upon DNA damage
to promote apoptosis [42]. GADD45A has also been
suggested to act as a backup for CDKN1A (also known
as p21), which is involved in p53-regulated DNA dam-
age repair, cell cycle arrest, and apoptosis [42, 43]. That
both of these genes were up-regulated after priming
treatment and only to a lower (CDKN1A) or no
(GADD45A) degree suggests a strong involvement of
the p53 pathway in the cellular tumor response to a
priming treatment with 177Lu-octreotate. At study end
(41 days after last injection), a response in apoptosis-
inhibiting processes was seen. In the 15 MBq group,
two genes (HSPB1 and ADORA2A) were up-regulated,
while one gene (CRYAB) was down-regulated in the 5
+ 10 MBq group. HSPB1, encoding a small heat shock
protein, has been shown to reduce activity of the pro-
apoptotic JNK signaling pathway (which acts via p53),
promoting survival in cells under stress. Several of the
other regulated apoptosis-related genes (APOE, BAX,
BNIP3, BNIP3L, IAPP, and LGALS1) have also been
shown to be associated with the JNK signaling pathway
[44–48]. CRYAB (also known as HSPB5), encoding a
heat shock protein similar to HSPB1, has previously
been shown to be able to inhibit both the “intrinsic”
and “extrinsic” apoptotic pathways [49]. These results,
in combination with the up-regulation (after priming
treatment) of ZAK (also known as MLK7), encoding a
MAP3 kinase that has been shown to activate JNK [50],
may explain the differences in tumor regrowth between
Dalmo et al. EJNMMI Research  (2017) 7:6 Page 15 of 16groups receiving priming and single administration. Non-
apoptotic-related cell death effects were not seen in the
current data, which indicates that apoptosis was the main
process involved in the reduction of tumor volume.
Conclusions
In summary, we observed an almost twofold higher
mean absorbed dose to tumor tissue when using priming
administration compared with a single administration
schedule. The mean absorbed dose to the dose-limiting
organs—i.e., the kidneys and bone marrow—were lower
or similar; therefore, we conclude that priming increases
the anti-tumor effect as well as expands the therapeutic
window of 177Lu-octreotate treatment.
Transcriptional analysis revealed activation of anti-
apoptotic genes in tumors in the 15 MBq treatment
group but pro-apoptotic activity in tumors from animals
receiving the 5 + 10 MBq treatment schedule. These
findings demonstrate that priming does not only influ-
ence the intensity of tumor response but also its bio-
logical quality with regard to cell survival. Several of the
genes regulated after 41 days have previously been
linked with JNK signaling, which may indicate that po-
tential biomarkers for tumor regrowth may be found in
the JNK signaling pathway.
These results of the present study might have clinical
implications, and priming administration is an interest-
ing optimization strategy for 177Lu-octreotate therapy of
neuroendocrine tumors. Further studies should be per-
formed to determine the mechanisms responsible for in-
creased anti-tumor effects and increased therapeutic
window obtained after priming administration.
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